ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of BRL 157.54 billion. The enterprise value is 154.69 billion.

Market Cap	157.54B
Enterprise Value	154.69B

Important Dates

The next confirmed earnings date is Thursday, April 30, 2026.

Earnings Date	Apr 30, 2026
Ex-Dividend Date	Feb 11, 2026

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.43%
Shares Change (QoQ)	-0.36%
Owned by Insiders (%)	0.52%
Owned by Institutions (%)	76.01%
Float	144.15M

Valuation Ratios

The trailing PE ratio is 19.25 and the forward PE ratio is 18.55.

PE Ratio	19.25
Forward PE	18.55
PS Ratio	5.30
PB Ratio	4.53
P/TBV Ratio	10.05
P/FCF Ratio	15.96
P/OCF Ratio	14.94
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.96, with an EV/FCF ratio of 15.68.

EV / Earnings	18.90
EV / Sales	5.73
EV / EBITDA	14.96
EV / EBIT	16.72
EV / FCF	15.68

Financial Position

The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.13.

Current Ratio	3.06
Quick Ratio	1.97
Debt / Equity	0.13
Debt / EBITDA	0.41
Debt / FCF	0.47
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 25.68% and return on invested capital (ROIC) is 26.60%.

Return on Equity (ROE)	25.68%
Return on Assets (ROA)	14.75%
Return on Invested Capital (ROIC)	26.60%
Return on Capital Employed (ROCE)	25.44%
Weighted Average Cost of Capital (WACC)	9.08%
Revenue Per Employee	2.80M
Profits Per Employee	772,094
Employee Count	10,600
Asset Turnover	0.69
Inventory Turnover	2.15

Taxes

In the past 12 months, ResMed has paid 1.83 billion in taxes.

Income Tax	1.83B
Effective Tax Rate	18.30%

Stock Price Statistics

The stock price has decreased by -16.72% in the last 52 weeks. The beta is 0.93, so ResMed's price volatility has been similar to the market average.

Beta (5Y)	0.93
52-Week Price Change	-16.72%
50-Day Moving Average	343.23
200-Day Moving Average	311.87
Relative Strength Index (RSI)	33.21
Average Volume (20 Days)	20

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	10.25

Income Statement

In the last 12 months, ResMed had revenue of BRL 29.73 billion and earned 8.18 billion in profits. Earnings per share was 55.69.

Revenue	29.73B
Gross Profit	18.28B
Operating Income	10.16B
Pretax Income	10.02B
Net Income	8.18B
EBITDA	11.15B
EBIT	10.16B
Earnings Per Share (EPS)	55.69

Balance Sheet

The company has 7.81 billion in cash and 4.67 billion in debt, giving a net cash position of 3.14 billion.

Cash & Cash Equivalents	7.81B
Total Debt	4.67B
Net Cash	3.14B
Net Cash Per Share	n/a
Equity (Book Value)	34.82B
Book Value Per Share	239.02
Working Capital	14.16B

Cash Flow

In the last 12 months, operating cash flow was 10.55 billion and capital expenditures -676.85 million, giving a free cash flow of 9.87 billion.

Operating Cash Flow	10.55B
Capital Expenditures	-676.85M
Depreciation & Amortization	896.68M
Net Borrowing	-49.96M
Free Cash Flow	9.87B
FCF Per Share	n/a

Margins

Gross margin is 61.47%, with operating and profit margins of 34.19% and 27.53%.

Gross Margin	61.47%
Operating Margin	34.19%
Pretax Margin	33.69%
Profit Margin	27.53%
EBITDA Margin	37.51%
EBIT Margin	34.19%
FCF Margin	33.19%

Dividends & Yields

This stock pays an annual dividend of 2.13, which amounts to a dividend yield of 0.76%.

Dividend Per Share	2.13
Dividend Yield	0.76%
Dividend Growth (YoY)	7.38%
Years of Dividend Growth	6
Payout Ratio	22.25%
Buyback Yield	0.43%
Shareholder Yield	1.19%
Earnings Yield	5.20%
FCF Yield	6.26%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ResMed has an Altman Z-Score of 12.89 and a Piotroski F-Score of 6.

Altman Z-Score	12.89
Piotroski F-Score	6